Cotización Palatin Technologies - PTN

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

0.96

Postura de Compra

Postura de Venta

Volume Operado de la Acción

32,334

0.92 Rango del Día 0.9669

0.68 Rango de 52 semanas 5.65

Capitalización de Mercado [m]

18.766M

Precio Anterior

0.9142

Precio de Apertura

0.92

Hora

0.944

Última hora de negociación

09:52:08

Volumen financiero

US$ 30,606

Precio Promedio Ponderado

0.946563

Volumen promedio (3 m)

285,123

Acciones en circulación

19,548,167

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.62

Beneficio por acción (BPA)

-1.52

turnover

4.49M

Beneficio neto

-29.74M

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

palatin.com

Sede

Wilmington, Delaware, USA

Fundado

Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker PTN. The last closing price for Palatin Technologies was US$0.91. Over the last year, Palatin Technologies shares have traded in a share price range of US$ 0.68 to US$ 5.65.

Palatin Technologies currently has 19,548,167 shares in issue. The market capitalisation of Palatin Technologies is US$17.87 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -0.62.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire CRANBURY, N.J., Oct...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 24, 2024 Data...

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 23, 2024 High...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.14	-12.7272727273	1.1	1.1	0.9	230616	0.970768	CS
4	-0.14	-12.7272727273	1.1	1.4	0.9	266695	1.14950347	CS
12	-0.68	-41.4634146341	1.64	1.72	0.68	285123	1.06312516	CS
26	-1.11	-53.6231884058	2.07	2.13	0.68	194852	1.25767676	CS
52	-0.93	-49.2063492063	1.89	5.65	0.68	339877	2.28521439	CS
156	0.585	156	0.375	8.6	0.1811	1069098	0.8529184	CS
260	0.1694	21.4267644827	0.7906	8.6	0.1811	1573167	0.75479002	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BIGYYieldmax Target 12 Big 50 Option Income ETF	49.78 (175.18%)	9.98k
SNOYYieldmax Snow Option Income Strategy ETF	US$ 21.5201 (22.55%)	32.42k
HYLNHyliion Holdings Corp	US$ 3.37 (15.81%)	1.05M
ETUT Rex 2X Long Ether Daily Target ETF	US$ 40.19 (13.79%)	30.87k
ETHTProshares Ultra Ether ETF	US$ 23.00 (12.36%)	517.84k
CATXPerspective Therapeutics Inc	US$ 3.255 (-47.24%)	3.78M
ROLRHigh Roller Technologies Inc	US$ 6.00 (-17.24%)	16.14k
MSTYYieldMax MSTR Option Income Strategy ETF	US$ 38.08 (-14.23%)	3.99M
CHROChannel Therapeutics Corporation	US$ 0.5353 (-13.55%)	39.38k
ETHDProshares Ultrashort Ether ETF	US$ 27.32 (-13.10%)	78.65k
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 0.8894 (9.42%)	711.96M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 27.23 (0.37%)	44.95M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3.1501 (2.94%)	33.4M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 6.1999 (0.32%)	25.43M
ETHU2x Ether ETF	US$ 8.30 (12.31%)	24.52M